XCUR

Exicure, Inc. NASDAQ Listed May 22, 2018

Healthcare ·Biotechnology ·US · exicuretx.com

$3.31

Mkt Cap $21.1M

52w Low $3.10 2.4% of range 52w High $11.86

50d MA $3.94 200d MA $4.86

P/E (TTM) -4.1x

EV/EBITDA -3.2x

P/B 5.2x

Debt/Equity 0.0x

ROE -126.0%

P/FCF -4.0x

RSI (14) —

ATR (14) —

Beta 4.01

50d MA $3.94

200d MA $4.86

Avg Volume 23.5K

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

SIC Code

2834

CIK (SEC)

1698530

Phone

847 673 1700

2430 North Halsted Street · Chicago, IL 60614 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 25, 2026	AMC	-18.60	-0.46	+97.5%	4.61	-0.4%	+0.0%	-4.1%	+1.1%	-4.9%	-1.6%	—
Nov 7, 2025	AMC	—	-0.39	—	3.96	+1.0%	-2.3%	-3.6%	-3.5%	+1.4%	+1.6%	—
Aug 8, 2025	AMC	—	-0.41	—	7.45	-4.0%	+1.7%	-3.7%	-2.1%	-4.2%	-2.9%	—
Jun 27, 2025	AMC	—	-0.45	—	5.89	+7.1%	+19.5%	-13.4%	-2.3%	+13.8%	-4.6%	—
Mar 18, 2025	AMC	—	-3.39	—	12.40	-2.4%	+4.0%	+5.1%	+3.6%	-3.4%	-2.2%	—
Nov 14, 2024	AMC	—	-0.57	—	3.18	-4.7%	-8.8%	+35.9%	+47.7%	+92.3%	-2.9%	—
Aug 13, 2024	AMC	—	-0.35	—	2.46	-2.8%	-25.6%	-1.1%	-0.6%	+10.0%	-5.6%	—
Jun 17, 2024	AMC	—	-0.50	—	1.58	+2.5%	+4.4%	-1.2%	+4.3%	-3.5%	-3.7%	—
Jun 6, 2024	AMC	—	-0.68	—	2.37	-11.4%	-16.5%	-13.6%	+1.8%	+6.3%	-9.2%	—
May 16, 2024	AMC	—	-3.05	—	2.60	-2.7%	-4.6%	-4.0%	-0.4%	-1.7%	-3.9%	—
Mar 27, 2023	AMC	-0.95	20.50	+2257.9%	4.50	-4.4%	-10.9%	-2.7%	+6.9%	+4.6%	+0.0%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Aug 16	Chardan Capital	Maintains	Neutral → Neutral	—	$11.60	$11.70	+0.9%	-3.4%	+1.8%	-6.6%	-9.9%	-4.2%
Dec 13	Chardan Capital	Downgrade	Buy → Neutral	—	$68.30	$60.00	-12.2%	-40.7%	-6.3%	+0.7%	+2.0%	-3.4%
Nov 23	Chardan Capital	Maintains	Buy → Buy	—	$68.70	$69.41	+1.0%	-0.1%	+19.4%	-9.3%	-4.1%	-1.3%
May 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$222.75	$217.50	-2.4%	-1.7%	+5.5%	-1.3%	+5.9%	+0.6%
Dec 18	BMO Capital	Maintains	Outperform → Outperform	—	$237.00	$271.50	+14.6%	+25.9%	+5.5%	-8.1%	+2.6%	-2.5%
Sep 17	Chardan Capital	Maintains	Buy → Buy	—	$306.75	$319.50	+4.2%	-0.7%	+1.0%	-6.8%	+0.5%	-3.6%
Nov 20	Guggenheim	Maintains	Buy → Buy	—	$390.00	$427.50	+9.6%	+0.4%	+1.5%	-4.9%	+7.5%	-1.8%
Nov 6	H.C. Wainwright	Maintains	Buy → Buy	—	$378.75	$385.50	+1.8%	-4.2%	+8.3%	-5.0%	-1.6%	+5.3%
Mar 26	Chardan Capital	Maintains	Buy → Buy	—	$364.50	$367.50	+0.8%	-3.3%	+2.1%	-4.2%	+2.2%	+0.0%
Jul 11	Ladenburg Thalmann	Maintains	Buy → Buy	—	$847.50	$862.50	+1.8%	+1.9%	-1.9%	+0.0%	+0.0%	+1.6%

Data updated apr 27, 2026 10:25am · Source: massive.com